Literature DB >> 14550270

Regulation of osteoclast protease expression by RANKL.

Y Wittrant1, S Theoleyre, S Couillaud, C Dunstan, D Heymann, F Rédini.   

Abstract

Receptor activator of NF-kappaB ligand (RANKL) is essential for osteoclast (OC) differentiation/activation and functions through its receptor RANK at the surface of the osteoclastic cells. This study investigated for the first time the direct effects of hRANKL on protease/protease inhibitor expressions and protease activities in purified rabbit osteoclast cultures, using semi-quantitative RT-PCR, gelatin zymography, and enzymatic assays. RANKL was shown to exert in vitro pro-resorptive effects by increasing osteoclast marker expressions (Tartrate resistant acid phosphatase (TRAP) and cathepsin K), MMP-9 expression, and pro-MMP-9 activity and by diminishing TIMP-1 expression, leading to an up-regulation of the MMP-9/TIMP-1 ratio.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14550270     DOI: 10.1016/j.bbrc.2003.09.084

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  13 in total

1.  RANK-Fc inhibits malignancy via inhibiting ERK activation and evoking caspase-3-mediated anoikis in human osteosarcoma cells.

Authors:  Toru Akiyama; Peter F M Choong; Crispin R Dass
Journal:  Clin Exp Metastasis       Date:  2010-04-11       Impact factor: 5.150

2.  Osteoclasts from patients with autosomal dominant osteopetrosis type I caused by a T253I mutation in low-density lipoprotein receptor-related protein 5 are normal in vitro, but have decreased resorption capacity in vivo.

Authors:  Kim Henriksen; Jeppe Gram; Pernille Høegh-Andersen; Rune Jemtland; Thor Ueland; Morten H Dziegiel; Sophie Schaller; Jens Bollerslev; Morten A Karsdal
Journal:  Am J Pathol       Date:  2005-11       Impact factor: 4.307

3.  Differential expression of tartrate-resistant acid phosphatase isoforms 5a and 5b by tumor and stromal cells in human metastatic bone disease.

Authors:  Serhan Zenger; Wentao He; Barbro Ek-Rylander; Daphne Vassiliou; Rickard Wedin; Henrik Bauer; Göran Andersson
Journal:  Clin Exp Metastasis       Date:  2010-10-22       Impact factor: 5.150

4.  High d(+)glucose concentration inhibits RANKL-induced osteoclastogenesis.

Authors:  Y Wittrant; Y Gorin; K Woodruff; D Horn; H E Abboud; S Mohan; S L Abboud-Werner
Journal:  Bone       Date:  2008-02-29       Impact factor: 4.398

5.  Targeting bone remodeling by isoflavone and 3,3'-diindolylmethane in the context of prostate cancer bone metastasis.

Authors:  Yiwei Li; Dejuan Kong; Aamir Ahmad; Bin Bao; Fazlul H Sarkar
Journal:  PLoS One       Date:  2012-03-07       Impact factor: 3.240

6.  Sympathetic Neurotransmitters Modulate Osteoclastogenesis and Osteoclast Activity in the Context of Collagen-Induced Arthritis.

Authors:  Dominique Muschter; Nicole Schäfer; Hubert Stangl; Rainer H Straub; Susanne Grässel
Journal:  PLoS One       Date:  2015-10-02       Impact factor: 3.240

7.  MMP9 polymorphism is associated with susceptibility to non-traumatic osteonecrosis of femoral head in a Chinese Han population.

Authors:  Yuan Liu; Yanfei Jia; Yuju Cao; Yan Zhao; Jieli Du; Feimeng An; Yuxin Qi; Xue Feng; Tianbo Jin; Jianping Shi; Jianzhong Wang
Journal:  Oncotarget       Date:  2017-08-24

8.  A single-nucleotide polymorphism in MMP9 is associated with decreased risk of steroid-induced osteonecrosis of the femoral head.

Authors:  Jieli Du; Wanlin Liu; Tianbo Jin; Zhenqun Zhao; Rui Bai; Huiqin Xue; Junyu Chen; Mingqi Sun; Xiyang Zhang; Guoqiang Wang; Jianzhong Wang
Journal:  Oncotarget       Date:  2016-10-18

9.  Expression of bone resorption genes in osteoarthritis and in osteoporosis.

Authors:  Darja Bitenc Logar; Radko Komadina; Janez Prezelj; Barbara Ostanek; Zoran Trost; Janja Marc
Journal:  J Bone Miner Metab       Date:  2007-06-25       Impact factor: 2.976

Review 10.  The Elusive Antifibrotic Macrophage.

Authors:  Adhyatmika Adhyatmika; Kurnia S S Putri; Leonie Beljaars; Barbro N Melgert
Journal:  Front Med (Lausanne)       Date:  2015-11-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.